ROBA PHARMA
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
15-07
micro format · 16 days before the deadline
2025
31-12
Financial
Liquidity more than 6 timescurrent ratio 8.69
The current ratio rises from 1.34 to 8.69. Short-term debt falls from €917,901 to €40,260.
30-12
Gazette deed
1 director appointed, 1 director resigningResignation: NV Balansa (director) · Permanent representatives: Ludwig GELDOF and Hanne DEWULF · Appointment: Vincent DEMEYERE (medebestuurder)6 points ▸
Gazette deed
1 director appointed, 1 director resigning
Resignation: NV Balansa (director) · Permanent representatives: Ludwig GELDOF and Hanne DEWULF · Appointment: Vincent DEMEYERE (medebestuurder)6 points ▸
- General meeting, 07-10-2025
- Director resignation, NV Balansa (director)
- Permanent representative, Ludwig GELDOF
- Director appointment, Vincent DEMEYERE (medebestuurder)
- Director in office, BV Vialma Invest (director)
- Permanent representative, Hanne DEWULF
08-07
micro format · 23 days before the deadline
2024
31-12
Financial
Equity above €200,000equity €308,336 ▲473%
After 3 profitable years in a row, equity reaches €308,336.
29-07
micro format · 2 days before the deadline
2023
30-05
abbreviated format · 62 days before the deadline
2022
31-12
Financial
Back to profitnet €307,919
The net result is €307,919, after one loss-making year.
18-07
micro format · 13 days before the deadline
2021
31-12
Financial
Weakest financial yearnet -€29,567
The net result drops to -€29,567, the lowest from 2019 to 2025. It recovers the following year.
30-07
micro format · 1 day before the deadline
2020
31-12
Financial
Back to profitnet €18,968
The net result is €18,968, after one loss-making year.
29-07
micro format · 2 days before the deadline
2018
05-11
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank